Dipeptidyl Peptidase 3 (DPP3)
Diagnosis, Prediction and Prognosis: 3 essentials for a novel biomarker
Dipeptidyl Peptidase 3 at a glance
Upon cell injury and death resultant from hypotension or tissue injury, DPP3, an intracellular peptidase, is released into the bloodstream. In numerous clinical studies, high blood DPP3 levels are strongly associated with organ failure and poor outcomes in critically ill patients.
We have demonstrated that the DPP3 biomarker has the potential to advance the prediction of organ function progression in critical care in addition to the standard-of-care markers.
Given the rapid advances in the DPP3 biomarker validation pipeline, DPP3 is a promising biomarker to help identify biologically active pathways in heterogeneous syndromes, such as septic shock and cardiogenic shock, and guide therapy escalation.
DPP3 in clinical practice
Immunoassay for DPP3 is available as
- Manual laboratory assay
- Point-of-Care platform
Sphingotest® IB10 DPP3:
- The DPP3 assay has been out-licensed to SphingoTec GmbH
- This test is intended for use in conjunction with the Nexus IB10 Analyzer and provides quantitative results in 22 minutes. The IB10 sphingotest® DPP3 is designed for professional use only and may be used in hospital central laboratories and in alternate care settings such as emergency departments, critical care units, and other sites where near-patient testing is practiced.
What is Procizumab (Ab1967)?
Procizumab is a humanized monoclonal antibody that specifically binds to circulating DPP3.
It is currently a first-in-class drug in a preclinical phase that targets and modulates DPP3 activity.
Procizumab has an innovative mode of action relevant to acute diseases associated with
massive cell death and the uncontrolled release of intracellular DPP3 into the bloodstream.
Diseased state and treatment with Procizumab
Procizumab blocks DPP3 in the bloodstream, inhibiting the degradation of bioactive peptides important for cardiovascular and renal function regulation. This blockade results in hemodynamic stabilization, due to improved cardiovascular function, and reduction of short-term mortality in preclinical models.
Who can benefit from Procizumab?
- Patients in circulatory shock due to sepsis and cardiac dysfunction.
- Patients in circulatory shock as a consequence of invasive surgeries
- Patients in circulatory shock due to burns
- Patients in circulatory shock due to acute or acute-on-chronic liver failure
- Preclinical Efficacy studies
In preclinical cardiovascular failure models, Procizumab has been shown to improve all clinically relevant endpoints in vivo. It normalizes ejection fraction and kidney function and reduces mortality. Proof of concept study in septic shock model in rats has shown the prompt effect of Procizumab in restoring cardiac function and improving hemodynamics
- Safety and tolerability studies
Studies in rodents have shown that Procizumab is safe and well-tolerated when injected intravenously in a broad dose range.
Toxicokinetic studies also indicate that Procizumab does not accumulate in organs.